Mainz Biomed N.V. develops and commercializes in-vitro diagnostic tests for early cancer detection. The company's primary product is ColoAlert, a molecular genetic stool test designed to screen for colorectal cancer, which is currently marketed in the United States and Europe. The company is also developing PancAlert, a stool-based diagnostic test for pancreatic cancer detection. Both products represent non-invasive screening approaches using molecular analysis of patient samples.
Beyond product sales, Mainz Biomed operates a clinical diagnostic laboratory that provides testing services and distributes its in-vitro diagnostic kits to third-party laboratories. The company has established a collaboration agreement with Thermo Fisher Scientific for the development and commercialization of colorectal cancer screening products, indicating a partnership-based approach to expanding market reach and capabilities.
The company operates with a small workforce of 19 full-time employees and maintains headquarters in Mainz, Germany, where it was founded in 2008. Its geographic presence spans the United States and Europe, focusing on markets with established demand for cancer screening diagnostics. As a Nasdaq-listed entity incorporated in the Netherlands, Mainz Biomed operates as a publicly traded company in the diagnostics and research sector within healthcare.
No 10-K filings found.